Quick Answer
Sigyn Therapeutics, Inc. reported Cash and Equivalents of $12.1 thousand for fiscal year 2024.
Sigyn Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2024 | $12.1K | +3.9% |
| 2023 | $11.7K | +39.9% |
| 2022 | $8.4K | -97.5% |
| 2021 | $341.0K | +304.0% |
| 2020 | $84.4K | +16780.4% |
| 2019 | $500.00 | -93.3% |
| 2018 | $7.5K | -21.8% |
| 2017 | $9.6K | -93.6% |
| 2016 | $149.6K | -76.6% |
| 2015 | $638.8K | +672346.3% |
| 2014 | $95.00 | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $85.6K | -48.1% | +18542.9% |
| June 30, 2025 | $459.00 | -99.1% | -96.4% |
| March 31, 2025 | $12.9K | -60.7% | +6.2% |
| December 31, 2024 | $12.1K | +3.9% | -92.6% |
| September 30, 2024 | $164.8K | +155.2% | +207.2% |
| June 30, 2024 | $53.6K | +127.0% | +63.4% |
| March 31, 2024 | $32.8K | -89.8% | +180.9% |
| December 31, 2023 | $11.7K | +39.9% | -81.9% |
- Sigyn Therapeutics, Inc. showed an increase of +3.9% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2014–2024 period, Sigyn Therapeutics, Inc.’s cash and equivalents has grown by 12683.2% (from $95.00 to $12.1 thousand).
- The most recent figure is from Sigyn Therapeutics, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on April 15, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: